<DOC>
	<DOCNO>NCT02902679</DOCNO>
	<brief_summary>An oral dose BMS-986177 administer End-stage Renal Dysfunction ( ESRD ) participant hemodialysis session evaluate safety , tolerability , pharmacokinetics patient population .</brief_summary>
	<brief_title>A Study Evaluate Safety Pharmacokinetics BMS-986177 Participants With End-stage Renal Dysfunction Chronic Stable Hemodialysis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Classified screen ESRD require hemodialysis least 3 time per week 3 month . Clinical , ECG , laboratory finding consistent renal dysfunction BMI 18.0 38.0 kg/m2 inclusive Subjects must receive unfractionated heparin dialysis treatment able withstand decrease establish heparin dose ( 75 % current dose ) Women Not child bear potential ( WNOCBP ) . Sexually active fertile men partner WOCBP must use nonhormonal highly effective birth control History uncontrolled unstable cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematopoietic , psychiatric , and/or neurological disease within 6 month screen Evidence history coagulopathy , prolong unexplained clinically significant bleeding , frequent unexplained bruise Current recent ( within 3 month study drug administration ) clinically significant gastrointestinal disease gastrointestinal surgery could interfere absorption study drug Any condition require anticoagulation , limited , atrial fibrillation , mechanical prosthetic valve , deep venous thrombosis , pulmonary embolism ( heparin require hemodialysis ) Need aspirin need P2Y12 antagonist therapy ( example clopidogrel , prasugrel , ticagrelor ) Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>